There were a reported 2.1 million new HIV infections in 2015, and 36.7 million people are currently living with HIV/AIDS globally. Vaccines could be an incredibly powerful tool in the fight against HIV/AIDS, with the potential to dramatically reduce the number of new HIV infections around the world. In continuation of Fenway Health’s decades-long commitment to treating and preventing HIV/AIDS, The Fenway Institute is excited to serve as a study site for several HIV vaccine trials, including HVTN 108.
HVTN 108 will examine both tolerability of a new HIV vaccine and the immune system’s response to it. It’s important to note that this vaccine is made using laboratory pieces of HIV and it is impossible for the vaccine to give someone HIV.
Eligible study participants are between the ages of 18 and 40, healthy, HIV-uninfected, and will be in Boston for the next 12 months. Participation for this study requires 12 visits over the course of one year which will include injections and follow up questionnaires. Volunteers will receive $1,175 compensation for their time.
Interested in joining this vaccine study and being a part of the future of HIV prevention? Click here to take an online screener. To learn more, please call 617.927.6450 or email firstname.lastname@example.org.
Want to receive email updates about what’s happening at Fenway Health? Sign up here.